mRNA 1283
Alternative Names: mRNA-1283; SpikevaxLatest Information Update: 17 Sep 2024
Price :
$50 *
At a glance
- Originator Moderna Therapeutics
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 12 Sep 2024 Moderna Therapeutics announces intention to submit NDA for approval for COVID-19 in 2024
- 25 Jul 2023 Moderna Therapeutics completes a phase I trial for COVID-2019 infections (Prevention) in USA (NCT04813796)
- 23 Mar 2023 Moderna Therapeutics completes a phase IIa trial in COVID-2019 infections (Prevention) in USA (IM) (NCT05137236)